Status:
COMPLETED
Seroquel XR in the Long Term Treatment of Schizophrenia
Lead Sponsor:
AstraZeneca
Conditions:
Relapse in Schizophrenia
Eligibility:
All Genders
18-70 years
Brief Summary
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients
Eligibility Criteria
Inclusion
- schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month
Exclusion
- Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
1606 Patients enrolled
Trial Details
Trial ID
NCT01202617
Start Date
September 1 2010
End Date
October 1 2011
Last Update
October 24 2011
Active Locations (61)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Baja, Hungary
2
Research Site
Balassagyarmat, Hungary
3
Research Site
Barcs, Hungary
4
Research Site
Berettyóújfalu, Hungary